EUCTR2004-001739-53-IT进行中（未招募）不适用
Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO0 个研究点开始时间: 2004年11月23日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse: a randomized phase II studyAcute lymphoblastic leukemia (ALL)LeukemiaCancerISRCTN86445183Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)120
招募中
不适用
ymfklier alloreactiviteit in niertransplantatie.kidney transplantation/ niertransplantatierejection/ rejectiealloreactivity/ alloreactiviteitlymph nodes/ lymfklierenNL-OMON26812Erasmus Medical Center
已完成
不适用
ymphnodes with and without Alemtuzumab to Measure Broad Alloreactivity against Donor Antigensniertransplantatierejection of kidney allograft10038430NL-OMON42749Interne Geneeskunde, sector Nefrologie en Niertransplantatie100
进行中（未招募）
不适用
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaEUCTR2010-024389-23-SEDepartment of Hematology30
尚未招募
不适用
Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse; A randomized phase II study.Acute lymphoblastic leukemia in relapseNL-OMON28605Stichting Hemato-Oncologie Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl120